ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
10
08
2021
accepted:
01
01
2022
pubmed:
26
2
2022
medline:
28
4
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
Selumetinib is a promising MAP (mitogen-activated protein) kinase (MEK) 1/2 inhibitor treatment for pediatric low-grade gliomas. We hypothesized that MR imaging-derived ADC histogram metrics would be associated with survival and response to treatment with selumetinib. Children with recurrent, refractory, or progressive pediatric low-grade gliomas who had World Health Organization grade I pilocytic astrocytoma with Each stratum comprised 25 patients. Stratum 1 responders showed lower values of SD of baseline ADC_total as well as a larger decrease with time on treatment in ADC_total mean, mode, and median compared with nonresponders. Stratum 3 responders showed a greater longitudinal decrease in ADC_total. In stratum 4, higher baseline ADC_total skewness and kurtosis were associated with shorter progression-free survival. When all 3 strata were combined, responders showed a greater decrease with time in ADC_total mode and median. Compared with sporadic OPHG, neurofibromatosis type 1-associated OPHG had lower values of ADC_total mean, mode, and median as well as ADC_enhancement mean and median and higher values of ADC_total skewness and kurtosis at baseline. The longitudinal decrease in ADC_total median during treatment was significantly greater in sporadic OPHG compared with neurofibromatosis type 1-associated OPHG. ADC histogram metrics are associated with progression-free survival and response to treatment with selumetinib in pediatric low-grade gliomas.
Sections du résumé
BACKGROUND AND PURPOSE
Selumetinib is a promising MAP (mitogen-activated protein) kinase (MEK) 1/2 inhibitor treatment for pediatric low-grade gliomas. We hypothesized that MR imaging-derived ADC histogram metrics would be associated with survival and response to treatment with selumetinib.
MATERIALS AND METHODS
Children with recurrent, refractory, or progressive pediatric low-grade gliomas who had World Health Organization grade I pilocytic astrocytoma with
RESULTS
Each stratum comprised 25 patients. Stratum 1 responders showed lower values of SD of baseline ADC_total as well as a larger decrease with time on treatment in ADC_total mean, mode, and median compared with nonresponders. Stratum 3 responders showed a greater longitudinal decrease in ADC_total. In stratum 4, higher baseline ADC_total skewness and kurtosis were associated with shorter progression-free survival. When all 3 strata were combined, responders showed a greater decrease with time in ADC_total mode and median. Compared with sporadic OPHG, neurofibromatosis type 1-associated OPHG had lower values of ADC_total mean, mode, and median as well as ADC_enhancement mean and median and higher values of ADC_total skewness and kurtosis at baseline. The longitudinal decrease in ADC_total median during treatment was significantly greater in sporadic OPHG compared with neurofibromatosis type 1-associated OPHG.
CONCLUSIONS
ADC histogram metrics are associated with progression-free survival and response to treatment with selumetinib in pediatric low-grade gliomas.
Identifiants
pubmed: 35210278
pii: ajnr.A7433
doi: 10.3174/ajnr.A7433
pmc: PMC8910799
doi:
Substances chimiques
AZD 6244
0
Benzimidazoles
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
455-461Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA081457
Pays : United States
Informations de copyright
© 2022 by American Journal of Neuroradiology.
Références
Ann Neurol. 1997 Feb;41(2):143-9
pubmed: 9029062
Lancet Oncol. 2020 Jun;21(6):e305-e316
pubmed: 32502457
AJR Am J Roentgenol. 2001 Aug;177(2):449-54
pubmed: 11461881
AJNR Am J Neuroradiol. 2020 May;41(5):874-881
pubmed: 32381545
Neuro Oncol. 2021 Oct 1;23(10):1777-1788
pubmed: 33631016
Br J Ophthalmol. 1969 Dec;53(12):793-8
pubmed: 5386369
Oncogene. 2009 May 21;28(20):2119-23
pubmed: 19363522
Acta Neuropathol Commun. 2020 Mar 12;8(1):30
pubmed: 32164789
J Neurooncol. 2015 May;122(3):491-6
pubmed: 25758812
Neuro Oncol. 2017 Aug 1;19(8):1135-1144
pubmed: 28339824
Lancet Oncol. 2019 Jul;20(7):1011-1022
pubmed: 31151904
Bioinformatics. 2008 Jun 15;24(12):1461-2
pubmed: 18441000
J Clin Oncol. 2006 Jun 1;24(16):2570-5
pubmed: 16735710
Neuro Oncol. 2018 Jan 22;20(2):160-173
pubmed: 29016845
AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1963-9
pubmed: 11733333
Pediatr Radiol. 2008 Dec;38(12):1293-9
pubmed: 18846370
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
N Engl J Med. 2020 Apr 9;382(15):1430-1442
pubmed: 32187457
Neurosurgery. 1996 Jun;38(6):1114-8; discussion 1118-9
pubmed: 8727140
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5957-62
pubmed: 23533272
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
pubmed: 11121466
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Acta Neuropathol. 2015 Jun;129(6):775-88
pubmed: 25792358
Radiology. 2013 Aug;268(2):532-7
pubmed: 23564715
Cancers (Basel). 2020 May 04;12(5):
pubmed: 32375301
J Magn Reson Imaging. 1999 Jan;9(1):53-60
pubmed: 10030650
Clin Cancer Res. 2004 Jun 1;10(11):3763-71
pubmed: 15173083
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Neuro Oncol. 2017 Jun 1;19(6):750-761
pubmed: 27683733
J Clin Oncol. 2007 Feb 20;25(6):682-9
pubmed: 17308273
AJNR Am J Neuroradiol. 2020 Apr;41(4):718-724
pubmed: 32241771
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
J Clin Oncol. 2017 Sep 1;35(25):2934-2941
pubmed: 28727518
Front Oncol. 2020 Feb 07;10:71
pubmed: 32117728
Neuro Oncol. 2016 May;18(5):725-34
pubmed: 26487690
AJNR Am J Neuroradiol. 2018 Mar;39(3):552-557
pubmed: 29301780
J Neurosurg. 2003 Jun;98(6):1170-4
pubmed: 12816259
AJNR Am J Neuroradiol. 2021 Apr;42(4):759-765
pubmed: 33574103
Neuro Oncol. 2014 Oct;16(10):1408-16
pubmed: 24803676
J Neurooncol. 2013 Jul;113(3):479-83
pubmed: 23673514